First U.S. patients treated in Anteris' global PARADIGM trial for DurAVR heart valve.

Anteris Technologies has enrolled and treated the first U.S. patients in its global PARADIGM trial, testing the DurAVR Transcatheter Heart Valve for severe aortic stenosis. This randomized trial compares DurAVR to existing TAVR devices, aiming to prove safety and effectiveness in about 1,000 patients. The trial's results will help guide future treatment decisions for aortic valve disease. The U.S. enrollment marks a key milestone following CMS reimbursement approval, expanding the trial's reach and recruitment potential.